QSAR analysis of the anticancer activity of 2,5-disubstituted 9-aza-anthrapyrazoles

QSAR and Combinatorial Science

Volumn 26, Issue 2, 2007, Pages 173-181

  Slavov, Svetoslav ^a   Atanassova, Mariyana ^a   Galabov, Boris ^a  

^a UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

9 Aza anthrapyrazoles; Activity; Anticancer; DNA binding; Electrostatic interactions; QSAR

Indexed keywords

COMPLEXATION; COMPUTATIONAL CHEMISTRY; ELECTROSTATICS; HYDROGEN BONDS; MOLECULAR GRAPHICS; MULTIPLE LINEAR REGRESSION;

3D-QSAR; 9-AZA-ANTHRAPYRAZOLE; ACTIVITY; ANTICANCER; ANTICANCER ACTIVITIES; DESCRIPTORS; DNA-BINDING; QSAR; QSAR ANALYSIS; QSAR MODEL;

HEURISTIC METHODS;

2 [2 (2 HYDROXY ETHYLAMINO)ETHYL] 5 (2 METHYLAMINO ETHYLAMINO)INDAZOLO[4,3 G,H]ISOQUINOLINE 6(2H) ONE; 2 [2 [(2 HYDROXYETHYL)AMINO]ETHYL] 5 [[2 (METHYLAMINO)ETHYL]AMINO]INDAZOLO[4,3 GH]ISOQUINOLIN 6(2H) ONE; 5 (2 DIMETHYLAMINO ETHYLAMINO) 2 [2 (2 HYDROXY ETHYLAMINO)ETHYL]INDAZOLO[4,3 G,H]ISOQUINOLINE 6 (2H) ONE; 5 [[2 (DIMETHYLAMINO)ETHYL]AMINO] 2 [2 [(2 HYDROXYETHYL)AMINO]ETHYL]INDAZOLO[4,3 GH]ISOQUINOLIN 6(2H) ONE; ANTINEOPLASTIC AGENT; LOSOXANTRONE; MITOXANTRONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG DNA BINDING; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRIC FIELD; ELECTRICITY; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

EID: 34250640695     PISSN: 1611020X     EISSN: 16110218     Source Type: Journal    
DOI: 10.1002/qsar.200530216     Document Type: Article

References (49)

1. H. Malonne, G. Atassi, Anticancer Drugs 1997, 8, 811-822.
2. A. P. Krapcho, M. J. Maresch, M. P. Hacker, L. Hazelhurst, E. Menta, A. Oliva, S. Spinelli, G. Beggiolin, F. C. Giuliani, G. Pezzoni, S. Tognella, Curr. Med. Chem. 1995, 2, 803-824.
3. F. Arcamone, S. Penco, Synthesys of New Doxorubicin Analogs, in: J. W. Lown (Ed.), Anthracycline and Anthracendione-based Anticancer Agents, Elsevier, New York, 1988.
4. R. K. Y. Zee-Cheng, C. C. Cheng, Drugs Future 1983, 8, 229-248.
5. S. K. Sengupta, Topoisomerase II Inhibitors, in: W. O. Foye (Ed.), Cancer Chemotherapeutic Angents, American Chemical Society, Washington DC, 1995, pp. 205-260.
6. H. Malonne, G. Atassi, Anticancer Drugs 1997, 8, 811-822.
7. G. N. Hortobagyi, Drugs 1997, 54 (Suppl. 4), S1-S7.
8. X. Thomas, E. Archimbaud, Hematol. Cell. Ther. 1997, 39, 63-74.
9. L. R. Wiseman, C. M. Spencer, Drugs Aging 1997, 10, 473-485.
10. F. M. Arcamone, Biochimie 1998, 80, 201-206.
11. P. J. Perry, S. M. Gowan, A. P. Reszka, P. Polucci, T. C. Jenkins, L. R. Kelland, S. Neidle, J. Med. Chem. 1998, 41, 3253-3260.
12. P. J. Perry, M. A. Read, R. T. Davies, S. M. Gowan, A. P. Reszka, A. A. Wood, L. R. Kelland, S. Neidle, J. Med. Chem. 1999, 42, 2679-2684.
13. W. H. Frishman, H. M. Sung, H. C. Yee, L. L. Liu, D. Keefe, A. I. Einzig, J. Dutcher, Curr. Probl. Cancer 1997, 21, 301-360.
14. A. Giantris, L. Abdurrahman, A. Hinkle, B. Asselin, S. E. Lipshultz, Crit. Rev. Oncol. Hematol. 1998, 27, 53-68.
15. A. Liwo, D. Jeziorek, T. Ossowski, D. Dyl, A. Tempczik, J. Tarasuik, M. Nowacka, E. Borowski, W. Woznicki, Acta Biochem. Pol. 1995, 42, 445-456.
16. D. Flauds, J. A. Balfour, P. Chrisp, H. D. Langtry, Drugs 1991, 41, 400-449.
17. C. J. Dunn, K. L. Goa, Drugs Aging 1996, 9, 122-147.
18. L. R. Wiseman, C. M. Spencer, Drugs Aging 1997, 10, 473-485.
19. A. Składanowski, J. Konopa, Br. J. Cancer 2000, 82, 1300-1304.
20. C. C. Cheng, R. K. Y. Zee-Cheng, The Design, Synthesis, and Development of a New Class of Potential Antineoplastic Anthraquinones, in: G. P. Ellis, G. B. West (Eds.), Progress in Medicinal Chemistry, Elsevier, New York, 1989, pp. 83-118.
21. A. P. Krapcho, M. E. Petry, Z. Getahun, J. J. Landi, Jr., J. Stallman, J. F. Polsenberg, C. E. Gallagher, M. J. Maresch, M. P. Hacker, F. C. Giuliani, G. Beggiolin, G. Pezzoni, E. Menta, C. Manzotti, A. Oliva, S. Spinelli, S. Tognella, J. Med. Chem. 1994, 37, 828-873.
22. L. A. Hazlehurst, A. P. Krapcho, M. P. Hacker, Biochem. Pharmacol. 1995, 50, 1087-1094.
23. L. A. Hazlehurst, A. P. Krapcho, M. P. Hacker, Cancer Lett. 1995, 91, 115-124.
24. P. De Isabella, M. Palumbo, C. Sissi, G. Capranico, N. Carenini, E. Menta, A. Oliva, S. Spinelli, A. P. Krapcho, F. C. Giuliani, F. Zunino, Mol. Pharmacol. 1995, 48, 30-38.
25. C. Sissi, G. Capranico, E. Menta, M. Palumbo, Mol. Pharmacol. 1996, 50, 838-845.
26. P. De Isabella, M. Palumbo, C. Sissi, N. Carenini, G. Capranico, E. Menta, A. Oliva, S. Spinelli, A. P. Krapcho, F. C. Giuliani, F. Zunino, Biochem. Pharmacol. 1997, 53, 161-169.
27. C. Sissi, S. Moro, A. P. Krapcho, E. Menta, M. Palumbo, Anticancer Drug Des. 1999, 14, 265-274.
28. A. P. Krapcho, E. Menta, A. Oliva, R. Di Domenico, L. Fiocchi, E. Maresch, C. E. Gallagher, M. P. Hacker, G. Beggiolin, F. C. Giuliani, G. Pezzoni, S. Spinelli, J. Med. Chem. 1998, 41, 5429-5444.
29. H. D. H. Showalter, J. L. Johnson, J. M. Hoftiezer, W. R. Turner, L. M. Werbel, W. R. Leopold, J. L. Shillis, R. C. Jackson, E. F. Elslager, J. Med. Chem. 1987, 30, 121-131.
30. D. C. Talbot, I. E. Smith, J. L. Mansi, I. Hudson, A. H. Calvert, S. E. Ashley, J. Clin. Oncol. 1991, 9, 2141-2147.
31. E. Cavalletti, L. Crippa, O. Bellini, E. Menta, R. Cavagnoli, D. Delbo, Proc. Am. Assoc. Cancer Res. 1993, 34, Abstr 2227.
32. L. H. Patterson, D. R. Newell, Cellular and Molecular Pharmacology of the Anthrapyrazole Antitumour Agents, in: S. Neidle, M. Waring (Eds.), Molecular Aspects of Anticancer Drug-DNA Interactions, Macmillan, New York, 1994, pp. 96-129.
33. I. R. Judson, Anticancer Drugs 1991, 2, 223-231.
34. H. Gogas, J. L. Mansi, Cancer Treat. Rev. 1995, 21, 541-552.
35. S. Berg, Crit. Rev. Oncol./Hematol. 1996, 22, 79-87.
36. G. N. Hortobagyi, Semin. Oncol. 1997, 24(Suppl. 17), S17-1-S17-4.
37. M. Barbu, N. Azarnia, H. Calvert, Ann. Oncol. 1994, 5(Suppl. 5), Abstr 288.
38. S. M. Walsh, W. M. Walley, M. Chandra, S. D. Huan, J. P. Veinot, L. A. J. Higginson, Can. J. Cardiol. 1995, 11, 419-422.
39. A. P. Krapcho, E. Menta, Drugs Future 1997, 22, 641-646.
40. C. Sissi, S. Moro, S. Richter, B. Gatto, E. Menta, S. Spinelli, A. P. Krapcho, F. Zunino, M. Palumbo, Mol. Pharmacol. 2001, 59, 96-103.
41. R. Supino, D. Polizzi, R. Pavesi, G. Pratesi, F. Guano, G. Capranico, M. Palumbo, C. Sissi, S. Richter, G. Beggiolin, E. Menta, G. Pezzoni, S. Spinelli, D. Torriani, N. Carenini, L. Dal Bo, F. Facchinetti, M. Tortoreto, F. Zunino, Oncology 2001, 61, 234-242.
42. A. R. Katritzky, V. S. Lobanov, M. Karelson (Eds.), CODESSA: Reference manual (version 2.0), Gainesville, Florida, 1994.
43. Chem-X, Chem-X was developed at Chemical Design Ltd. (now part of Accelrys), 1998.
44. I. C. Muszynski, L. Scapozza, K.-A. Kovar, G. Folkers, Quant. Struct.-Act. Relat. 1999, 18, 342-353.
45. Z. Weifan, E. Ganesh Srinivas, C. Sung Jin, A. Tropsha, 215th ACS National Meeting, Comparative studies of 3D (CoMFA) and 2D QSAR methods, Book of Abstracts, American Chemical Society, Washington, 1998.
46. C. Hansch, A. Leo, Fundamentals and Applications in Chemistry and Biology, in: S. R. Heller, (Ed.), Exploring QSAR, American Chemical Society, Washington, DC, 1995.
47. M. J. S. Dewar, E. G. Zoebisch, E. F. Healy, J. J. P. Stewart, J. Am. Chem. Soc. 1985, 107, 3902-3909.
48. U. C. Singh, P. K. Weiner, J. Caldwell, P. A. Kollman, AMBER Version 3, University of California, San Francisco.
49. H. Kubinyi, Pharm. Acta Helv. 1995, 69, 259-269.